Matt, who ran the Kaeberlein lab at the University of Washington from 2006 to 2023, rounded up several former lab members for a chat at the recent 52nd annual meeting of the American Aging Association (AGE) in Madison, Wisconsin. The group included assistant and tenured professors at various institutions around the United States, startup founders, and prospective PhD students with geroscience research interests that span the microbiome, mitochondrial dysfunction, frailty, metabolism, sex differences in aging, and more. In this episode, Matt and his former lab members pool their collective knowledge to engage in a lively conversation (and sometimes debate) about longevity interventions such as metformin, acarbose, and sauna use. In their discussion, they touch on hot-off-the-press positive results, unpublished data, and planned research from their respective research groups and labs. They also bring up nuances to recent published work, including results from the Interventions Testing Program on various interventions that Matt discussed in a previous podcast episode.
0:00 Introduction
1:07 Lab member introductions
10:49 Let’s grade interventions: for, against, don’t know
11:19 Methylene blue
12:31 Dasatinib and quercetin (D + Q)
13:51 Caffeine
14:04 Protein restriction
15:02 Branched-chain amino acid restriction
17:07 Hyperbaric oxygen therapy
19:04 Sauna
19:34 Cold plunges
21:48 Parabiosis
25:52 NAD+
26:52 AKG
29:55 Metformin
32:20 GLP-1 agonists
34:00 Resveratrol
35:02 Rapamycin
36:07 Acarbose
36:39 3-hydroxyanthranilic acid (3HAA)
37:05 ORB-1284
37:34 The weirdest thing you’ve ever done for your longevity
46:50 Wrapping up